Insight Molecular Diagnostics Inc.
NASDAQ:IMDXMedical - Diagnostics & Research
+$0.13 today
- Market cap
- $52.08M
- Beta
- 1.79
- P/E (TTM)
- -3.9
- EPS (TTM)
- -$1.39
Volume 0.64M
Average 0.38M
Returns on capital
Insight Molecular Diagnostics Inc. management
Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.
Return Metrics
ROE, ROIC & ROA over time
ROE
159.6%
avg -93.0%
ROIC
-197.4%
avg -121.5%
ROA
-195.0%
avg -102.6%
Analysis
ROE is currently the strongest return metric at 159.6% versus its period average of -93.0%. 1 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Leadership
Who runs the company?
Review the executive team, tenure, compensation, and ownership.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|
Joshua Riggs | President, Chief Executive Officer & Director | USD 662.79K | 43 | — | — |
Ekkehard Schutz | Chief Science Officer | USD 552.01K | — | — | — |
Andrea Susan James | Chief Financial Officer | USD 536.58K | 44 | — | — |
James Liu | Vice President of Accounting, Treasurer, Controller & Principal Accounting Officer | USD 303.25K | 30 | — | — |
Michael D. West | Scientific Advisor, Co-CEO of Biotime,Inc. & President of Biotime,Inc. | — | 73 | 60.00K | 0.22% |
Paul R. Billings FACP | Consulting Chief Medical Officer | — | 74 | — | — |
Peter Hong | Vice President, General Counsel & Secretary | — | — | — | — |
Steven Tahmooressi | Vice President of Marketing | — | — | — | — |
Yuh-Min Chiang | Chief Technology Officer | — | — | — | — |
Sandra O'Donald | Senior Vice President of Business Operations | — | — | — | — |
Donnie Purto | SVP of Sales & Sales Operations | — | — | — | — |
Compensation is shown in the reported currency; data updated Nov 7, 2026.
Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Feb 16, 2016.
Insider trading
Are insiders buying or selling?
Follow recent insider purchases and sales reported on Form 4.
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
14
$5.69M
Sells
0
$0.00
Net Transaction Value
+$5.69M
Net buying
Most Active
BROADWOOD PARTNERS, L.P.
14 transactions
Transactions sorted by date, descending.
| Type | |||
|---|---|---|---|
| Apr 27, 26Apr 27, 2026 | BROADWOOD PARTNERS, L.P. Indirect | Buy | $0$0.00 |
| Apr 27, 26Apr 27, 2026 | BROADWOOD PARTNERS, L.P. Direct | Buy | $913.1K$913,133.89 |
| Apr 24, 26Apr 24, 2026 | BROADWOOD PARTNERS, L.P. Indirect | Buy | $0$0.00 |
| Apr 24, 26Apr 24, 2026 | BROADWOOD PARTNERS, L.P. Direct | Buy | $137.1K$137,083.10 |
| Apr 23, 26Apr 23, 2026 | BROADWOOD PARTNERS, L.P. Indirect | Buy | $0$0.00 |
| Apr 23, 26Apr 23, 2026 | BROADWOOD PARTNERS, L.P. Direct | Buy | $982K$982,034.45 |
| Apr 20, 26Apr 20, 2026 | BROADWOOD PARTNERS, L.P. Indirect | Buy | $0$0.00 |
| Apr 20, 26Apr 20, 2026 | BROADWOOD PARTNERS, L.P. Direct | Buy | $158K$157,966.72 |
| Apr 17, 26Apr 17, 2026 | BROADWOOD PARTNERS, L.P. Indirect | Buy | $0$0.00 |
| Apr 17, 26Apr 17, 2026 | BROADWOOD PARTNERS, L.P. Direct | Buy | $143.3K$143,251.11 |
1–10 of 14
Summary
Insiders reported 14 buys worth $5.69M and 0 sells worth $0.00 over the last 12 months. That adds up to net buying of $5.69M. BROADWOOD PARTNERS, L.P. was the most active insider with 14 transactions.
Growth analysis
Is management growing the business?
Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A2 analysts |
| Revenue | N/A | N/A | +61.8% | +75.7% (3yr)2 analysts |
| Net Income | N/A | N/A | N/A | N/A2 analysts |
| EBIT | N/A | N/A | N/A | N/A2 analysts |
Analysis
Recent growth has been strongest in Revenue at +61.8% over three years. Forward estimates point to Revenue at +75.7% (3yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Who does Insight Molecular Diagnostics Inc. compete with?
Open similar companies to compare how their management teams allocate capital.
Questions
Management questions
Common questions about IMDX's management, answered from reported figures.
Who manages IMDX?
Insight Molecular Diagnostics Inc. (IMDX) lists 11 active executives. The top listed executive is Ekkehard Schutz, Chief Science Officer.
Are IMDX insiders buying or selling?
Recent insider activity shows net buying of $60.61M.
Continue the stock analysis
Jump to another research area for this company.